Goldfield (GV) -- is a leading provider of electrical construction and maintenance services in the energy infrastructure industry in the southeastern United States. The company specializes in installing and maintaining electrical transmission lines for a wide range of electric utilities. Goldfield is also involved in the development of high-end condominium projects on Florida's east coast.
Technical Factors:
- 96% Barchart technical buy signal
- Trend Spotter buy signal
- 21 new highs and up 27.27% in the last month
- Relative Strength Index
- Trades at .42 with a 50 day moving average of .36
There are no Wall Street brokerage analysts following this stock
On Motley Fool there is only one member giving an opinion but it is a buy
PDL BioPharma (PDLI) -- Protein Design Labs Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a leader in the development of humanized antibodies, PDL has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products.
Technical Factors:
- 96% Barchart technical buy signal
- Trend Spotter buy signal
- 14 new highs and up 14.65% in the last month
- Relative Strength Index 67.12% and rising
- Trades around 6.36 with a 50 day moving average of 5.68
Fundamental Factors:
- Wall Street brokerage analysts published 3 buy and 4 hold recommendations
- Sales projected to increase by 12.50% this year and 9.10% next year
- Earnings are estimated to increase by 31.50% this year,19.70% next year and 26.00% annually for the next 5 years
General Investor Sentiment:
- 1,213 investors following this stock on Motley Fool
- CAPS members 860 to 42 that the stock will beat the market
- The more experienced All Stars agree 299 to 12
NOTE: Since Jim Cramer advised a sell on this stock on 3/8/2011 the stock surged up 11.62%
Guaranty Bancorp (GBNK) -- is a bank holding company with one wholly owned bank subsidiary, Guaranty Bank and Trust Company. Guaranty Bank and Trust Company provides banking and other financial services, including real estate, construction, commercial and industrial, energy, consumer and agriculture loans, to consumers and small and medium-sized businesses, including the owners and employees of those businesses, through 36 community banking branches in the Colorado Front Range. Guaranty Bank also provides trust services, including personal trust administration, estate settlement, investment management accounts and self-directed IRAs.
Technical Factors:
- 100% Barchart short term technical buy signals
- Trend Spotter buy signal
- 13 new highs and up 10.85% in the last month
- Relative Strength Index 42.11% and rising
- Trades around 1.43 with a 50 day moving average of 1.29
Fundamental Factors:
- Only 1 Wall Street brokerage is following this stock and he has a hold recommendation released
- Sales are expected to increase by 26.70% next year
- Earnings are expected to increase by 73.80% this year and increase annually by 10.70% for the next 5 years
General Investor Sentiment:
- The 46 investors following this stock on Motley Fool are very split on its future
- CAPS members are evenly split 18 to 18 that the stock will continue to beat the market
- The experienced All Stars are negative by a 3 to 7 vote
Medallion Financial (TAXI) -- is a specialty finance company that originates and services loans that finance taxicab medallions and various types of commercial loans.
Technical Factors:
- 100% Barchart technical buy signal
- Trend Spotter buy signal
- 13 new highs and up 5.74% in the last month
- Relative strength Index 63.60% and rising
- Trades around 8.89 with a 50 day moving average of 8.39
Fundamental Factors:
- Only 1 Wall Street brokerage analysts following this issue and he has a hold
- Sales are projected to be just slightly negative this year
- Earnings are another thing with a growth of 51.00% projected for this year, 6.20% for next year and 10.00% annually for the next 5 years
Vonage (VG) -- is a leading provider of digital phone services with over two million subscriber lines. Their award-winning technology enables anyone to make and receive phone calls with a touch tone telephone almost anywhere a broadband Internet connection is available. They offer feature-rich and cost-effective communication services that offer users an experience similar to traditional telephone services.The Residential Premium Unlimited and Small Business Unlimited calling plans offer consumers unlimited local and long distance calling, and popular features like call waiting, call forwarding and voicemail - for one low, flat monthly rate. Vonage's service is sold on the web and through national retailers including Best Buy, Circuit City, Wal-Mart Stores Inc. and Target and is available to customers in the U.S., Canada and the United Kingdom.
Technical Factors:
- 96% Barchart technical buy signal
- Trend Spotter buy signal
- 13 new highs and up 26.35% in the last month
- Relative Strength Index 68.388% and rising
- Trades around 5.21 with a 50 day moving average of 4.45
Fundamental Factors:
- Wall Street brokerage analysts have 1 strong buy, 1 buy and 1 hold recommendations released
- Sales are expected to increase by 1.00% this year and 2.00% next year
- Earnings are estimated to increase by 285.70% this year, 3.80% next year and 2.50% annually for the next 5 years
General Investor Sentiment:
- Over 1900 investors on Motley Fool have expressed opinions on this stocks
- CPAS members vote 475 to 1,105 taht the stock will NOT beat the market
- The more experienced All Stars are also negative 83 to 330
Jim Van Meerten is an analyst for Marketocracy Capital Management. He shares his knowledge and experience from over 40 years of investing in stocks, mutual funds and ETFs on Barchart.com in his daily blog -- Barchart Portfolio Blogs.
No comments:
Post a Comment